Long-term and short-term models for studying anthracycline cardiotoxicity and protectors

Cardiovascular Toxicology

Volumn 7, Issue 2, 2007, Pages 135-139

  Robert, Jacques ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT BERGONIÉ   (France)

Author keywords

Anthracyclines; Cancer chemotherapy; Cardiotoxicity; Dexrazoxane; Doxorubicin; Rat isolated perfused heart

Indexed keywords

DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; PACLITAXEL; PIRARUBICIN; RAZOXANE;

CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ASSESSMENT; CONFERENCE PAPER; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENTIATION; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; THEORETICAL MODEL; VALIDITY;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; HEART DISEASES; HUMANS; MODELS, BIOLOGICAL; PERFUSION;

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 34548306827     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-007-0022-4     Document Type: Conference Paper

References (18)

1. Shan, K., Lincoff, A. M., & Young, J. B. (1996). Anthracycline- induced cardiotoxicity. Annals of Internal Medicine, 125, 47-58.
2. Rhoden, W., Hasleton, P., & Brooks, N. (1993). Anthracyclines and the heart. British Heart Journal, 70, 499-502.
3. Pein, F., Sakiroglu, O., Dahan, M., Lebidois, J., Merlet, P., Shamsaldin, A., Villain, E., de Vathaire, F., Sidi, D., & Hartmann, O. (2004). Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. British Journal of Cancer, 91, 37-44.
4. Herman, E. H., & Ferrans, V. (1986). Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemotherapy and Pharmacology, 16, 102-106.
5. van Acker, F. A., Hulshof, J. W., Haenen, G. R., Menge, W. M., van der Vijgh, W. J., & Bast, A. (2001). New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. Free Radical Biology and Medicine, 31, 31-37.
6. Herman, E. H., Zhang, J., Lipshultz, S. E., Rifai, N., Chadwick, D., Takeda, K., Yu, Z. X., & Ferrans, V. J. (1999). Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. Journal of Clinical Oncology, 17, 2237-2243.
7. Maral, R., Bourat, G., Ducrot, R., Fournel, J., Ganter, P., Julou, L., Koenig, F., Myon, J., Pascal, S., Pasquet, J., Populaire, P., de Ratuld, Y., & Werner, G. H. (1967). Toxicologic study and experimental antitumor activity of rubidomycin (13,057 R.P.). Pathologie et Biologie, 15, 903-908.
8. Jaenke, R. S. (1974). An anthracycline antibiotic-induced cardiomyopathy in rabbits. Laboratory Investigation, 30, 292-304.
9. Ferrans, V. J., Sanchez, J. A., & Herman, E. H. (1992). Pathologic anatomy of animal models of anthracycline-induced cardiotoxicity. In F. M. Muggia, M. D. Green, & J. L. Speyer (Eds.), Cancer treatment and the heart (pp. 89-113). Baltimore, MD: The Johns Hopkins University Press.
10. Van Vleet, J. F., Greenwood, L., Ferrans, V. J., & Rebar, A. H. (1978). Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. American Journal of Veterinary Research, 39, 997-1010.
11. Herman, E. H., Ferrans, V. J., Jordan, W., & Ardalan, B. (1981). Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Research Communications in Chemical Pathology and Pharmacology, 31, 85-97.
12. Herman, E. H., el-Hage, A. N., Ferrans, V. J., & Ardalan, B. (1985). Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicology and Applied Pharmacology, 78, 202-214.
13. Pouna, P., Bonoron-Adèle, S., Gouverneur, G., Tariosse, L., Besse, P., & Robert, J. (1995). Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemotherapy and Pharmacology, 35, 257-261.
14. Pouna, P., Bonoron-Adèle, S., Gouverneur, G., Tariosse, L., Besse, P., & Robert, J. (1996). Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. British Journal of Pharmacology, 117, 1593-1599.
15. Platel, D., Pouna, P., Bonoron-Adèle, S., & Robert, J. (1999). Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs, 10, 671-676.
16. Platel, D., Bonoron-Adèle, S., Dix, R. K., & Robert, J. (1999). Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin. British Journal of Cancer 81, 24-27.
17. Platel, D., Pouna, P., Bonoron-Adèle, S., & Robert, J. (2000). Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicology and Applied Pharmacology, 163, 135-140.
18. Plandé, J., Platel, D., Tariosse, L., & Robert, J. (2006). Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicology Letters, 161, 37-42.